Patients with underlying gallbladder and biliary tract disease. Disorders of gallbladder, biliary tract and pancreas
Conditions
Interventions
Intervention 1: Intervention group: patients who receive low dose of hyoscine N-butylbromide ( 5 mg ) from Exir pharmaceutical company during cholangiopancreatography. The frequency of drug use depend
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: age above 18 years Underlying disease needs cholangiopancreatography Existence of Duodenal peristaltism that Interference with canolation
Exclusion criteria
Exclusion criteria: Previous cardiovascular problems ( heart failure, myocardial infarction, second and third degree AV block ) Acute pancreatitis and cholangitis before procedure Severe hypotension ( <100 mmhg ) Pregnancy and breastfeeding History of previous Allergy to Hyoscine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of anti motility duodenal response. Timepoint: Before starting the procedure, five minutes after the injection of hyoscine, and at the end of procedure. Method of measurement: observing the duodenal motility ( presence or absence of peristaltism) by physician during cholangiopancreatography (ERCP). | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of blood pressure changes, cardiac rate and rhythm and o2 satuartion changes. Timepoint: Before starting the procedure, five minutes after the injection of hyoscine, and at the end of procedure. Method of measurement: cardiac monitoring for blood pressure and heart rate and pulsoximetry for o2 saturation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contacthassan salmanroghani
Yazd University of Medical Sciences
Outcome results
None listed